MedTrace Logo

Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients

NCT00760032 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-12-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether plasma levels of lipopolysaccharide binding protein (LBP) are correlated with PBMN pro- and anti-inflammatory cytokine secretion, as well as with the development of severe infectious events in cirrhotic patients with ascites. As a secondary purpose, the study will evaluate the effect of a prophylactic administration of ciprofloxacin on LBP, cytokines and infections in the same patients.

Conditions

Interventions

DRUG

Ciprofloxacin

Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.

DRUG

Placebo

Placebo capsules, one capsule per day during four weeks.

Sponsors & Collaborators

  • Laboratorios Senosiain, S.A. de C.V.

    collaborator INDUSTRY

  • Florencia Vargas-Vorackova

    lead OTHER

Principal Investigators

  • Florencia Vargas-Vorackova, M.D., Ph.D. · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00760032 on ClinicalTrials.gov